Efficacy, innovativeness, clinical trials, endpoints, and price of drugs with FDA approval for non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Michaeli, C. T. [1 ]
Michaeli, J. C. [2 ]
Desai, A. [3 ]
Albers, S. [4 ]
Michaeli, D. T. [5 ]
机构：
[1] UMM Univ Klinikum Mannheim, Abt Personalisierte Onkol Schwerpunkt Lungenkar, Mannheim, Germany
[2] Univ Hosp Munich, Dept Gynecol & Obstet, Breast Ctr & CCC Munich, BZKF, Munich, Germany
[3] Univ Alabama Birmingham, Div Hematol & Oncol, Dept Med, Birmingham, AL USA
[4] Tech Univ Munich, Klin & Poliklinik Unfallchirurgie, Klinikum Rechts Isar, Munich, Germany
[5] Natl Ctr Tumor Dis NCT Heidelberg, Dept Med Oncol, Heidelberg, Germany
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1386
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1331P
引用
收藏
页码：S845 / S845
页数：1
相关论文
共 50 条
  • [21] Eicosanoids in non-small cell lung cancer (NSCLC)
    Johnson, D. H.
    Horn, L.
    Zhao, Z.
    Milne, G.
    Morrow, J.
    Sandler, A.
    Shyr, Y.
    Carbone, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Gemcitabine in non-small cell lung cancer (NSCLC)
    Manegold, C
    Zatloukal, P
    Krejcy, K
    Blatter, J
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (01) : 29 - 42
  • [23] A review of vaccine clinical trials for non-small cell lung cancer
    Nemunaitis, J.
    Nemunaitis, J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (01) : 89 - 102
  • [24] Development of clinical trials for non-small cell lung cancer drugs in China from 2005 to 2023
    Jia, Wanying
    Yu, Haiyan
    Song, Li
    Wang, Jian
    Niu, Shuyu
    Zang, Guojie
    Liang, Mingjie
    Liu, Jinwei
    Na, Risu
    FRONTIERS IN MEDICINE, 2023, 10
  • [25] Challenges in regulatory marketing approval of drugs for the treatment of advanced non-small cell lung cancer based on non-inferiority trials
    Sridhara, Rajeshwari
    Malik, Shakuntala
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S540 - S540
  • [26] Accuracy of Clinical Stage in Resectable Non-small Cell Lung Cancer (NSCLC)
    Gwon, H. R.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S520 - S521
  • [27] Clinical implications of telomerase activity in non-small cell lung cancer (NSCLC)
    Ramírez, JL
    Sancho, E
    Núñez, L
    Sánchez, JJ
    Balañá, C
    López, P
    Martín, C
    Monzó, M
    Rosell, R
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S39 - S39
  • [28] Clinical implications of telomerase activity in non-small cell lung cancer (NSCLC)
    Pifarre, A
    Monzo, M
    Martin, C
    Sanchez, JJ
    Barnadas, A
    Rosell, R
    ANNALS OF ONCOLOGY, 1998, 9 : 92 - 92
  • [29] Patients with advanced non-small cell lung cancer (NSCLC): Are research biopsies a barrier to participation in clinical trials?
    Lim, Charles Henry
    Sung, Mike
    Nouriany, Nazanin Ziapour
    Sawczak, Magdalena
    Paul, Tuhina
    Perera-Low, Nicole
    Feld, Ronald
    Liu, Geoffrey
    Shepherd, Frances A.
    Leighl, Natasha B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] FDA drug approval summary:: Pemetrexed for injection (Alimta®) for the treatment of non-small cell lung cancer
    Cohen, MH
    Johnson, JR
    Wang, YC
    Sridhara, R
    Pazdur, R
    ONCOLOGIST, 2005, 10 (06): : 363 - 368
12345